PHILADELPHIA, June 25,
2024 /PRNewswire/ -- Carisma Therapeutics
Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a
clinical-stage biopharmaceutical company focused on discovering and
developing innovative immunotherapies, today announced that
Steven Kelly, President and Chief
Executive Officer, will participate in a fireside chat at the
Stifel 2024 Cell Therapy Forum on Tuesday,
July 9th at 9:10 am
ET.
An audio webcast of the event will be available on the
Company's Investor Events section of the Investor
Relations webpage and will be archived for a limited time following
the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-stifel-2024-cell-therapy-forum-302180822.html
SOURCE Carisma Therapeutics Inc.